OMERACT®
Outcome Measures in Rheumatology

BUSINESS ADVISORY COMMITTEE SPONSORSHIP PROSPECTUS

2026

We are excited to present our OMERACT Business Advisory Committee Sponsorship Prospectus. Your support as a valued industry partner will help us achieve our mission and make a significant impact. We invite you to partner with us and be a part of this transformative journey.

PREPARED BY

OMERACT



ABOUT US

OMERACT is a global, volunteer-driven, not for profit organisation committed to improving outcomes for patients with autoimmune and musculoskeletal diseases through advancing the design and quality of clinical studies.

Through rigorous, consensus-based methodology and a global network of Working Groups, OMERACT develops Core Outcome Sets (COS) that define what should be measured (domains) in clinical trials and observational studies, and identifies how those domains should be measured using valid, reliable, and feasible instruments. OMERACT outputs are widely used in clinical research and have informed regulatory decision-making for new therapies.

WHY INDUSTRY PARTNERS WITH OMERACT

Sponsoring OMERACT connects your organization with the global standard-setting body for outcome measurement in rheumatology. For more than 30 years, OMERACT has shaped the endpoints that define clinical success in trials worldwide, across both emerging and established disease areas.

OMERACT delivers value across the drug development lifecycle:

- **Early pipeline and emerging diseases:** OMERACT provides structured, consensus-based methods to justify disease relevance, outcome selection, and feasibility in areas where evidence and precedent are limited. This foundational work supports investment decisions and early regulatory dialogue.

- **Established indications:** OMERACT enables timely refinement of domains and instruments to reflect evolving patient experience, new therapies, and regulatory expectations, helping sponsors maintain relevance and efficiency in high-prevalence conditions.

By partnering with OMERACT, sponsors:

- Help shape the science that shapes trials by contributing to the development of internationally adopted Core Outcome Sets
- Engage with global leaders in outcomes research, clinical trials, health technology assessment, and regulatory science
- Demonstrate a strong commitment to patient-centered research through collaboration with one of the largest global networks of Patient Research Partners (PRPs)
- Reduce research waste and trial risk by supporting standardized, comparable, and meaningful outcome measurement
- Align with OMERACT's recognized role in regulatory science, with relevance to agencies such as FDA and EMA

Sponsorship represents a strategic investment in methodological rigour, credibility, and long-term impact rather than promotional activity.

SCIENTIFIC INDEPENDENCE AND RESPONSIBLE INDUSTRY ENGAGEMENT

OMERACT is an independent, not-for-profit organization. Scientific integrity and methodological independence are foundational principles of all OMERACT activities.

- Industry sponsors do not influence scientific endorsement decisions
- All Working Group outputs follow the OMERACT Filter methodology, including assessment of truth, discrimination, and feasibility
- Consensus decisions are made through transparent, multi-collaborator processes that include clinicians, researchers, patients, and methodologists
- Sponsorship supports infrastructure, coordination, and engagement, not predetermined scientific outcomes

OMERACT also serves as a neutral forum where emerging and legacy outcome measures can be evaluated together. This helps sponsors navigate regulatory expectations around endpoint redundancy, coexistence of measures, and evidence requirements.

This structure ensures compliance with industry governance standards while enabling constructive scientific dialogue.

YEAR-ROUND VALUE BEYOND THE BIENNIAL CONFERENCE

While the OMERACT Biennial Conference is a cornerstone of consensus-building, OMERACT's work continues year-round, supporting both long-term methodological development and near-term, actionable insights.

BAC sponsors benefit from ongoing engagement opportunities, including:

- Participation in virtual workshops with voting rights, where methodological and domain-level questions are addressed
- Regular updates on Working Group progress, emerging domains, and methodological advances
- Structured opportunities for dialogue with OMERACT leadership through the Business Advisory Committee
- Early awareness of new initiatives, pilot work, and areas of growing regulatory relevance

This continuous engagement allows sponsors to remain connected to evolving science and to identify both foundational and near-term opportunities for impact.

PATIENT VOICE AS A COMPETITIVE ADVANTAGE

Authentic, structured patient involvement is a defining strength of OMERACT and a key differentiator from other scientific societies and consortia. Patient Research Partners (PRPs) are embedded throughout OMERACT's methodology, governance, and Working Group activities, contributing as equal collaborators rather than advisors at the margins.

WHY PATIENT VOICE MATTERS FOR INDUSTRY

Early-stage and emerging programs
In areas such as myositis and other rare or evolving diseases, patient insight is critical for understanding disease burden, feasibility, and acceptability of study procedures. PRP input informs considerations such as recovery time after biopsies, visit burden, outcome relevance, and meaningful change thresholds, helping sponsors design studies that are both ethical and operationally feasible.

Established and high-prevalence conditions
In mature indications such as rheumatoid arthritis, psoriatic arthritis, and osteoarthritis, integrating new forms of patient voice helps ensure outcome measures remain relevant as treatments and expectations evolve. This renewed patient perspective can re-energize scientific dialogue, support refinement of endpoints, and maintain regulatory credibility in well-studied disease areas.

Patient Partnership as an Industry Asset
OMERACT does not treat patient engagement as symbolic. Patient partnership is implemented through reproducible, methodologically rigorous processes that support:

- Ethical trial design grounded in lived experience
- Feasible outcome selection and protocol development
- Transparent documentation of patient input for regulatory and HTA audiences
- Stronger justification of endpoint relevance and meaningfulness

By packaging patient-partner methods as a core component of outcome development, OMERACT provides industry sponsors with a competitive advantage: trials and endpoints that are more defensible, more relevant, and more aligned with both patient priorities and regulatory expectations. featuring OMERACT methods and outputs.

OMERACT BY THE NUMBERS

35+ Active Working Groups
Advancing Core Outcome Set development across diseases, domains, imaging, biomarkers, and composite measures.

2,000+ OMERACTers worldwide
Collaborators from across six continents including over 200 Patient Research Partners (PRPs).

30+ Years of Leadership
Trailblazing outcome measurement methods that shape clinical trials, guidelines, and regulatory approvals.

Biennial Global Conference
Bringing together international experts for consensus-building, workshops, and scientific exchange.

3000+ peer-reviewed publications
Featuring OMERACT methodologies and working group outputs



World map showing OMERACT members highlighting the global reach of researchers, Patient Research Partners, Emerging Leaders, and Fellows.

MEET OUR BUSINESS ADVISORY COMMITTEE CO-CHAIRS

Meet our Business Advisory Committee Co-Chairs. With a shared passion for advancing patient outcomes in rheumatology, they lead our efforts to secure strategic sponsorship and partnerships. As passionate advocates, our BAC Co-Chairs represent OMERACT in external forums, promoting the importance of outcome measures in rheumatology research.

HOW INDUSTRY ENGAGES WITH OMERACT WORKING GROUPS

Industry engagement in OMERACT is governed through the Business Advisory Committee (BAC) to ensure transparency, consistency, and fairness.

- BAC membership is required for industry representatives to participate in OMERACT Working Groups or attend OMERACT meetings
- Participation involves contributing scientific and methodological expertise, not directing outcomes
- Access to Working Groups is equitable across sponsors and topic areas
- Data sharing is voluntary and governed by Working Group and OMERACT policies

All Working Group funding is administered centrally by OMERACT to support sustainability and methodological consistency across the organization.

WORKING GROUPS

OMERACT categorizes working groups into six thematic areas, each addressing unique facets of Core Outcome Set Development:

1. Disease Theme: These groups focus on particular diseases or anatomical areas. They define and standardize what should be measured in clinical trials and studies within that condition ensuring that outcomes reflect what truly matters to patients.

ANCA-Associated Vasculitis
Behçet's Syndrome
Calcium Pyrophosphate Deposition (CPPD)
Chronic Nonbacterial Osteomyelitis (CNO)
Foot & Ankle Disorders
Gout
Hip and Knee Osteoarthritis
Juvenile Idiopathic Arthritis (JIA)
Large-Vessel Vasculitis
Late-Stage Knee and Hip Osteoarthritis
Myositis
Patient Outcomes in Longitudinal Observational Studies (POLOS)-RA
Polymyalgia Rheumatica (PMR)
Psoriatic Arthritis (PsA)
Rheumatoid Arthritis
Scleroderma Vascular Disease
Shoulder Disorders
Sjögren's Disease
Systemic Lupus Erythematosus (SLE)

2. Imaging & Biomarkers: These Working Groups focus on developing, validating, and standardizing outcome measures derived from imaging technologies and biological samples that can be used reliably in clinical trials and observational studies.

MRI Taskforce
Synovial Tissues in RCT
Ultrasound

WORKING GROUPS

3. Domain Specific: These groups look across diseases to study common aspects of health such as pain, fatigue, safety, and work productivity. Their work promotes harmonization across studies, making findings more comparable and generalizable.

Glucocorticoid-Related Adverse Events
Flares in JIA
Flares in OA
OMERACT Foundational Domains
Pain
Remission in RA-patient perspective
Safety
Worker Productivity

4. Methodology: Methods Working Groups strengthen the foundation of OMERACT by improving how Core Outcome Sets are developed. They refine methods for domain selection, instrument evaluation, and meaningful patient engagement, ensuring all Working Groups apply consistent, transparent, and evidence-based approaches.

Composite Outcomes
Contextual Factors
Equity, Diversity & Inclusivity (EDI) Working Group
Patient Research Partner Engagement
Patient Preferences to Value Health Outcomes for RCT's (PPRCT)
Surrogate Outcomes

5. Bolt-On: develop add-on outcomes that can be integrated into existing Core Outcome Sets to address evolving research priorities and emerging concepts. Bolt-Ons expand and enhance existing frameworks rather than replacing them, allowing OMERACT to remain responsive and inclusive as science and patient experience evolve.

Shared Decision Making

CORPORATE SPONSORSHIP

Corporate sponsorship is a two-year commitment, billed annually. Benefits increase by tier, reflecting depth of engagement and access within BAC governance.

PLATINUM $100,000 AND ABOVE

- Three seats on the OMERACT Business Advisory Committee
- Three invitations to the annual OMERACT Business Advisory Committee meeting
- Three waived all inclusive registrations for the OMERACT Biennial Conference
- Unlimited access for representatives to participation in any OMERACT Working Group
- Voting rights for five representatives in virtual workshops
- Dedicated advisory meeting with OMERACT leadership (available virtually or in person, by request)
- Podium recognition at OMERACT conferences
- Recognition as Platinum Partner across OMERACT platforms

GOLD $65,000 – $99,999

- Two seats on the OMERACT Business Advisory Committee
- Two invitations to the annual OMERACT Business Advisory Committee meeting
- One waived all-inclusive registrations for the OMERACT Biennial Conference
- Access for up to five representatives to participation in any OMERACT Working Group
- Voting rights for three representatives in virtual workshops
- Podium recognition at all OMERACT conferences
- Recognition as Gold Partner across OMERACT platforms

SILVER $50,000 - $64,999

- One seat on the OMERACT Business Advisory Committee
- One invitation to the annual OMERACT Business Advisory Committee meeting
- Podium recognition at all OMERACT conferences
- Access for two representatives to participation in any OMERACT Working Group
- Voting rights for one representative in virtual workshops
- Recognition as Silver Partner partner across OMERACT platforms

BRONZE $20,000

(For companies without approved products)

- One seat on the OMERACT Business Advisory Committee
- One invitation to the annual OMERACT Business Advisory Committee meeting
- One waived all-inclusive registrations for the OMERACT Biennial Conference
- Access for two representatives to participation in any OMERACT Working Group
- Voting rights for two representative in virtual workshops
- Podium recognition at all OMERACT conferences
- Recognition as Bronze Partner partner across OMERACT platforms

A STRATEGIC PARTNERSHIP

OMERACT
Outcome Measures in Rheumatology

OMERACT welcomes dialogue with current and prospective sponsors to explore engagement opportunities within BAC governance and policies. Sponsorship is designed to support rigorous science, meaningful patient involvement, and outcomes that matter in clinical research and regulatory decision-making.

CONTACT US

+613-794-1355

www.omeract.org

admin@omeract.org

COMPLIANCE AND INTERNAL REVIEW FAQ

1. Is OMERACT independent from industry sponsors?
Yes. OMERACT is an independent, not-for-profit research collaboration. Industry sponsorship supports OMERACT's infrastructure, coordination, and engagement activities but does not influence scientific decisions, endorsements, or outcomes.

2. Can sponsors influence which outcomes or instruments are endorsed?
No. All scientific decisions, including endorsement of Core Outcome Sets and measurement instruments, follow OMERACT's established consensus methodology and are made through transparent, multi-stakeholder processes that include clinicians, researchers, methodologists, and Patient Research Partners.

3. How does OMERACT ensure compliance with industry governance standards?
Industry engagement is governed through the Business Advisory Committee (BAC). This structure provides clear guardrails, consistent access, and transparent engagement while maintaining separation between sponsorship and scientific decision-making.

4. Is participation considered promotional or marketing activity?
No. OMERACT activities are scientific and methodological in nature. Sponsorship and participation are non-promotional and focused on improving outcome measurement science, trial design, and patient-centered research.

5. Can industry representatives attend OMERACT meetings or Working Groups?
Yes, provided the company is a member of the Business Advisory Committee at an appropriate sponsorship tier. This requirement ensures equitable access, transparency, and consistent governance across all industry participants.

6. Are there restrictions on data sharing?
Yes. Data sharing is voluntary and governed by OMERACT and Working Group policies. Sponsors may choose whether to share proprietary data, and no sponsor is required to disclose confidential or commercially sensitive information.

COMPLIANCE AND INTERNAL REVIEW FAQ CONTINUED

7. How is sponsor funding managed?
All sponsorship funding is administered centrally by OMERACT. This ensures financial transparency, accountability, and alignment with OMERACT's mission and governance principles.

8. Can sponsorship be tailored to specific areas of interest?
Engagement may be discussed within the framework of BAC governance and policies. OMERACT welcomes dialogue to align sponsor interests with appropriate scientific activities while maintaining independence and fairness across sponsors.

How this fits with company medical governance

Participation in OMERACT is well aligned with typical medical affairs and outcomes research governance structures. Engagement is scientific, non-promotional, and focused on methodology, endpoint selection, and patient-centered measurement rather than product-specific messaging. Activities are comparable to involvement in academic consortia, guideline development initiatives, or outcomes research collaborations. BAC participation offers a structured, transparent forum that supports internal compliance review, documentation, and audit requirements while enabling medical affairs teams to contribute to pre-competitive science that informs trial design, regulatory strategy, and evidence generation across therapeutic areas.